Alteogen
Alteogen is a leading bio company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | N/A | Series A | |
| Total Funding | 000k | ||
| KRW | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (26 %) | 235 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (10 %) | (23 %) | (1 %) | 40 % |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (16 %) | (28 %) | (3 %) | 61 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 19 % | 65 % | 26 % | 24 % |
Source: Company filings or news article
Related Content
Alteogen Inc. is a biopharmaceutical company focused on developing innovative biologics, including long-acting bio-betters, proprietary antibody-drug conjugates (ADCs), and monoclonal antibody biosimilars. The company operates in the global pharmaceutical market, targeting both large pharmaceutical companies and biotechnology firms as its primary clients. Alteogen's business model revolves around research and development, licensing out its proprietary technologies, and forming strategic alliances with international partners. Revenue is generated through licensing agreements, milestone payments, and royalties from commercialized products. The company's core technologies include Hybrozyme Technology, a novel human hyaluronidase PH20 variant, and Fusion Technology for next-generation long-acting biologics.
Keywords: biopharmaceuticals, biologics, bio-betters, ADCs, biosimilars, Hybrozyme, Fusion Technology, licensing, strategic alliances, R&D.